Antigens
COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein. COVID-19 Spike Protein undertakes the functions of virus binding with host cell receptors, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design. COVID-19 Spike Protein mRNA-LNP can be used for RNA delivery, vaccine formulation and design targeting SARS-CoV-2.
COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) is an mRNA encoding the SARS-CoV-2 spike protein with enhanced performance via chemical modification. COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) replaces natural uridine (UTP) with N1-Me-Pseudo UTP, which effectively reduces immunogenicity and improves stability and translation efficiency. The 3' UTR of COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) optimizes AU-rich elements through HuR anchor sites, exhibiting higher translation efficiency. COVID-19 Spike Protein mRNA is widely used in COVID-19-related scientific research and vaccine development.
OVA mRNA (N1-Me-Pseudo UTP) is an mRNA encoding chicken ovalbumin. The substitution with N1-Me-Pseudo UTP (m1Ψ) improves protein expression and reduces innate immune response. OVA mRNA binds to the STING-activating polymer PD18 and is encapsulated in optimized lipid nanoparticles to construct an mRNA vaccine platform (PD18 LNP). This platform not only enhances the lymphatic delivery efficiency and protein expression of mRNA, but also potently adjuvates immune responses via activating the STING pathway.
OVA mRNA (5moU) encodes the ovalbumin (OVA) protein, a member of the serpin superfamily and the predominant glycoprotein found in egg whites. It is a commonly used antigen for immunization and biochemical studies and is an established model allergen for airway hyper-responsiveness.
